Clinical Trials
30 trialsChemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Mayo Clinic
LEAP-009
Merck Sharp & Dohme LLC
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
ELEVATE HNSCC
Gilead Sciences
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Dana-Farber Cancer Institute
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
City of Hope Medical Center
NEOPBOSCC
Hospital of Stomatology, Wuhan University
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
M.D. Anderson Cancer Center
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Nebraska
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Bristol-Myers Squibb
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Wake Forest University Health Sciences
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
Barbara Ann Karmanos Cancer Institute
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
Radiation Therapy Oncology Group
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Masonic Cancer Center, University of Minnesota
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
Dana-Farber Cancer Institute
Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil
Emory University
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
University of Michigan Rogel Cancer Center
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Case Comprehensive Cancer Center
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
Dana-Farber Cancer Institute
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
Dana-Farber Cancer Institute
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
Radiation Therapy Oncology Group
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Vanderbilt-Ingram Cancer Center